The Double-Edged Sword: Radical Numerics' $50M Bet on Biological AI

SAN FRANCISCO, CA – June 15, 2026

A new player has entered the high-stakes world of artificial intelligence with a mission so audacious it borders on science fiction: to build a "general biological intelligence." Radical Numerics launched today, armed with a formidable $50 million seed round and a team of pioneers from the front lines of AI research. Led by Emergence Capital, the investment signals a profound shift in market sentiment, where the very code of life is now seen as the next great platform for technological disruption. But as the company aims to unify biology into a single, designable system, it walks a razor's edge between creating cures for humanity's worst diseases and unlocking unprecedented biological risks.

From Open-Source Code to Life Code

The credibility behind Radical Numerics' bold vision isn't just its war chest; it's the proven track record of its founders. The team, which includes CEO Eric Nguyen, Chief AI Scientist Michael Poli, President Stefano Massaroli, and CTO Armin Thomas, is the same group that created the field of generative genomics with their landmark models, Evo and Evo 2. These weren't just academic exercises; they were foundational shifts in how AI interacts with biology.

Evo, a 7-billion-parameter model published on the cover of Science, was the first AI to truly "read" and "write" DNA at scale, learning from millions of microbial genomes. Its successor, Evo 2, published in Nature, expanded this capability exponentially. With 40 billion parameters and trained on over 128,000 whole genomes—including human—Evo 2 can reason over vast stretches of genetic code, identifying disease-causing mutations with stunning accuracy and even designing novel genomes. By making these powerful models—the largest open-source AI projects in any biological domain—fully accessible, the team fostered a global research community while simultaneously establishing their own unparalleled expertise. This history is crucial; it shows a pattern of building foundational platforms, not just single-point solutions.

The 'Why' Behind the $50 Million Buy

In a venture landscape showing signs of "AI fatigue," a $50 million seed round for a research lab is a resounding statement. It reflects a strategic bet on a new, more tangible frontier for AI—one where digital code directly manipulates biological matter. Emergence Capital, a firm known for its enterprise software savvy, leading this round is particularly telling. It’s a validation that the applications of general biological intelligence are not merely scientific curiosities but are poised to become core enterprise infrastructure for the entire life sciences industry.

"Most labs bolt safety on at the end. Radical Numerics built it into the foundation," said Gordon Ritter, Founder and General Partner at Emergence Capital. "They've paired frontier-model capability with real biosecurity expertise to open a scientific field that didn't exist before. That combination is rare, and it's why we led this round."

Ritter’s comment gets to the heart of the investment thesis. The market isn't just buying a technology; it's buying a philosophy. The participation of firms like Obvious Ventures, which focuses on "world-positive" impact, and an early pre-seed investment from Stripe CEO Patrick Collison, a known advocate for ambitious technological progress, further solidifies the narrative. Investors are betting that the team that democratized generative genomics is the right one to commercialize it responsibly.

A Mandate of Duality: Curing Disease, Containing Danger

The core of the Radical Numerics strategy—and its greatest challenge—is its explicit dual mandate: to advance biological design for human health while simultaneously building the defenses to protect it. This is not a talking point; it is the company's operational blueprint.

On one hand, the company is previewing its next-generation model, Omnii, which is already showing state-of-the-art results in identifying genetic variants linked to Alzheimer's disease. By creating multimodal models that reason across DNA, RNA, and proteins at once, Radical Numerics is developing tools that could lead to breakthroughs in complex disease diagnostics. A partnership with a cancer diagnostics company to apply Omnii to pancreatic and multi-cancer detection is the first tangible step, promising a more unified diagnostic signal than current tools can offer.

On the other hand, the company confronts the dark side of its own potential. "The same models that can help cure disease may also lower the barrier to designing harmful biology," acknowledged CEO Eric Nguyen. "These forces are inseparable. Biology will be the most consequential application of AI." This candid admission is backed by action. The company is actively partnering with a national lab to use its models, including Omnii, to detect and characterize pathogens, whether naturally occurring or—critically—AI-generated. This positions Radical Numerics not just as a creator of powerful tools, but as a necessary gatekeeper in an era of potential bioterrorism enabled by AI. This biodefense-by-design approach is a critical differentiator in a field where ethics are often an afterthought.

The New Competitive Frontier in Biology

Radical Numerics does not enter an empty field. Giants like Google DeepMind, with its AlphaFold success, and established players like Insitro and Recursion Pharmaceuticals are already applying AI to biology with immense resources. However, this new entity is carving out a unique niche. While competitors often focus on specific modalities like protein folding or high-throughput screening for drug discovery, Radical Numerics is pursuing a more holistic, foundational prize: a single, unified model of biology itself.

Its strategy of building general biological intelligence, starting with the open-source success of Evo and now moving toward proprietary models like Omnii, is a classic platform play. By aiming to create the underlying "operating system" for biology, the company could become indispensable to a vast ecosystem of pharmaceutical, diagnostic, and agricultural partners. The early results from Omnii—achieving state-of-the-art performance in both disease variant identification and AI-pathogen detection—suggest its multimodal approach is already yielding a powerful competitive advantage. The journey to true general biological intelligence will be long and fraught with ethical minefields, but with this launch, the race has officially begun.